Aneuploidy Enables Cross-Adaptation to Unrelated Drugs
Open accessThe DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Abstract
Aneuploidy is common both in tumor cells responding to chemotherapeutic agents and in fungal cells adapting to antifungal drugs. Because aneuploidy simultaneously affects many genes, it has the potential to confer multiple phenotypes to the same cells. Here, we analyzed the mechanisms by which Candida albicans, the most prevalent human fungal pathogen, acquires the ability to survive both chemotherapeutic agents and antifungal drugs. Strikingly, adaptation to both types of drugs was accompanied by the acquisition of specific whole-chromosome aneuploidies, with some aneuploid karyotypes recovered independently and repeatedly from very different drug conditions. Specifically, strains selected for survival in hydroxyurea, an anticancer drug, acquired cross-adaptation to caspofungin, a first-line antifungal drug, and both acquired traits were attributable to trisomy of the same chromosome: loss of trisomy was accompanied by loss of adaptation to both drugs. Mechanistically, aneuploidy simultaneously altered the copy number of most genes on chromosome 2, yet survival in hydroxyurea or caspofungin required different genes and stress response pathways. Similarly, chromosome 5 monosomy conferred increased tolerance to both fluconazole and to caspofungin, antifungals with different mechanisms of action. Thus, the potential for cross-adaptation is not a feature of aneuploidy per se; rather, it is dependent on specific genes harbored on given aneuploid chromosomes. Furthermore, pre-exposure to hydroxyurea increased the frequency of appearance of caspofungin survivors, and hydroxyurea-adapted C. albicans cells were refractory to antifungal drug treatment in a mouse model of systemic candidiasis. This highlights the potential clinical consequences for the management of cancer chemotherapy patients at risk of fungal infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






![Fig. 7. Effect of HU pre-exposure on cross-adaptation to caspofungin. Parental strain SC5314 was passaged daily for 7 days in YPD+HU (IC50; 2.814 mg/ml) at 37 °C, washed, and growth was measured on either solid (A) or liquid (B) medium. (A) ∼1 × 105 cells were plated on YPD plates (with or without CSP [100 ng/ml] as indicated) and incubated at 37 °C for 3 days. (B) Passaged cells (with or without HU from the pre-exposure period above) were plated on YPD at a cell density of ∼200 CFUs/plate and incubated at 37 °C for 24 h. From each plate, 94 colonies from the control YPD treatment (gray curves), and 94 colonies from the YPD+HU treatment (blue curves) were randomly selected and grown at 37 °C in YPD with or without CSP (100 ng/ml); parental strain without pre-exposure was also tested (red curves). Growth was measured as absorbance at 600 nm every 15 min. (C) Strains evolved for 7 days as above were analyzed by spot assays. Serial dilutions of cell suspension were spotted (3 µl/spot) on YPD plates supplemented with the indicated concentrations of HU or CSP and incubated at 37 °C for 48 h. Each condition was tested a minimum of three independent times. Growth is represented in a heat map comparing strains with or without Chr2 trisomy (Chr2x3, euploid, respectively), as described in methods.](https://figures.cochat.ai/paper-figures/33dd5a021e3e44cabf27e77683ac988e/aneuploidy-enables-cross-adaptation-to-unrelated-drugs-figure-7.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent work in C. albicans demonstrated that exposure to the cancer chemotherapeutic hydroxyurea, or the ER stress-inducing agent tunicamycin selects for trisomy of chromosome 2, which also enables tolerance to the echinocandin caspofungin66,67.”
From Molecular mechanisms governing antifungal drug resistance (2023) · cites this paper as [66]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Yang et al. found three negative regulators of echinocandin susceptibility on chr5. These are CHT2, encoding a glycosylphosphatidylinositol (GPI)-dependent chitinase, a covalently bound cell wall protein, PGA4, encoding a GPI-anchored cell surface 1,3-β-d-glucanosyltransferase, and CSU51 encoding another putative GPI-anchored protein [132].”
From Insight into the Mechanisms and Clinical Relevance of Antifungal Heteroresistance (2025) · cites this paper as [132]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Copy number variations, including whole-chromosome aneuploidy and shorter-range amplifications, are genome changes that can increase resistance32,43–49.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [48]
The cited source says what the claim attributes to it.
In the citing paper
“C. albicans’ heteroresistance to echinocandins is related to chr2, as chr2 trisomy can be induced after exposure to caspofungin [132].”
From Insight into the Mechanisms and Clinical Relevance of Antifungal Heteroresistance (2025) · cites this paper as [132]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Fiji: an open-source platform for biological-image analysis
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012) · Nature Methods · doi:10.1038/nmeth.2019 · Cited by 66,890 · cited 1×
“The images were processed by a custom Fiji/ ImageJ plugin (Schindelin et al. 2012; Schneider et al. 2012).”
MethodNIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638 · cited 1×
“The images were processed by a custom Fiji/ ImageJ plugin (Schindelin et al. 2012; Schneider et al. 2012).”
MethodHidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284 · cited 1×
“A leading cause of such infections is Candida albicans, a common member of the commensal microbiome (Brown et al. 2012; Mousset et al. 2014; Lai et al. 2019).”
BackgroundPappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191
Isogenic strain construction and gene mapping in Candida albicans.
Fonzi, W. A., & Irwin, M. Y. (1993) · Genetics · doi:10.1093/genetics/134.3.717 · Cited by 1,687
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ1194 · Cited by 1,298 · cited 1×
“This also implies that cancer chemotherapy with HU has the potential to promote cross-adaptation to CSP. Relevance In Vivo CSP is a first-line antifungal drug used in clinics for the treatment of systemic candidiasis (Pappas et al. 2016).”
BackgroundGenome evolution across 1,011 Saccharomyces cerevisiae isolates
Peter, J., De Chiara, M., Friedrich, A., Yue, J.-X., Pflieger, D., Bergström, A., Sigwalt, A., Barre, B., Freel, K., Llored, A., et al. (2018) · Nature · doi:10.1038/s41586-018-0030-5 · Cited by 1,117 · cited 1×
“albicans: wild and clinical isolates of the model yeast Saccharomyces cerevisiae often carry aneuploidies as well (Sunshine et al. 2015; Gallone et al. 2016; Gasch et al. 2016; Zhu et al. 2016; Peter et al. 2018).”
BackgroundEffects of Aneuploidy on Cellular Physiology and Cell Division in Haploid Yeast
Torres, E. M., Sokolsky, T., Tucker, C. M., Chan, L. Y., Boselli, M., Dunham, M. J., & Amon, A. (2007) · Science · doi:10.1126/science.1142210 · Cited by 935 · cited 1×
“Aneuploidies often incur a fitness cost, reducing adaptation to many growth conditions (Torres et al. 2007; Sheltzer and Amon 2011).”
Background
Research works printed but not linked: 1
- O'Neill J. 2016 Tackling drug-resistant infections globally: final report and recommendations. Available from: https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf, last accessed March 5, 2019.
Cited by
Items 101–104 of 104
A multiplex droplet digital PCR assay for chromosome copy-number determination in Candida albicans
Maciel, E. I., Ursuegui, S., Ahmed‐Seghir, S., Maufrais, C., Roy, S., Gautier, C., Brandt, P., Jovelet, C., Pitayu-Nugroho, L., & Ene, I. V. (2026) · G3 Genes Genomes Genetics · doi:10.1093/g3journal/jkag201
“For example, monosomy of chromosome 5 (Chr5) promotes tolerance to fluconazole and caspofungin (Yang et al. 2019), trisomy of Chr2 confers cross-resistance to caspofungin, tunicamycin, and hydroxyurea (Yang et al. 2021a), while duplication of the left arm of Chr5 (iso-Chr5L) drives fluconazole…”
Zande, P. V., Gervais, N. C., Schell, E. R., Zajac, P., Metzner, K., Shapiro, R. S., & Selmecki, A. M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.07.743545
Sun, L.-L., Li, H., Yan, T.-H., Cao, Y.-B., Jiang, Y.-Y., & Yang, F. (2023) · doi:10.3389/fmicb.2023.1137083.s008
Self-citationAvramovska, O., Smith, A. C., Rego, E., & Hickman, M. A. (2022) · doi:10.3389/ffunb.2022.984377.s003
Metadata
- Authors
- Yang, F., Teoh, F., Tan, A. S. M., Cao, Y., Pavelka, N., & Berman, J.
- Affiliations
- Tel Aviv University (IL)
- Agency for Science, Technology and Research (SG)
- Shanghai University of Traditional Chinese Medicine (CN)
- Corresponding author
- Pavelka, Norman
- Berman, Judith
- Venue
- Molecular Biology and Evolution
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-04-27
- Volume
- 36
- Issue
- 8
- Pages
- 1768-1782
- ISSN
- 0737-4038 (ISSN-L)
- 1537-1719
- PMC
- PMC6657732
- OpenAlex
- W2940793950
- Cited by
- 101
- References
- 91
- Citations by year
- 2026: 9 · 2025: 13 · 2024: 13 · 2023: 15 · 2022: 15 · 2021: 17 · 2020: 13 · 2019: 6
- FWCI
- 4.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Molecular Biology and Evolution (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- European Research Council (340087)
- Agency for Science, Technology and Research (JCO/1437a00117)
- Singapore Immunology Network
- National Science Foundation of China (81872910)
- A*STAR Graduate Scholarship
- PBC China-Israel Postdoctoral Fellowship Program
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Evolution and Genetic Dynamics
- Keywords
- aneuploidy, cross-adaptation, Candida albicans, drug tolerance, antifungal resistance, chemoresistance, hydroxyurea, caspofungin, fluconazole, trisomy, monosomy, chromosome 2, chromosome 5, stress response pathways, systemic candidiasis, fungal pathogens
- MeSH terms
- Caspofungin, Adaptation, Biological, Aneuploidy, Animals, Antifungal Agents, Antineoplastic Agents, Candida albicans, Hydroxyurea, Chromosomes, Fungal, Calcineurin, Drug Resistance, Fungal, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.